Table 3.

Overview of reasons for a BICLA non-response/SRI(4) response at week 52 in TULIP-1 among BICLA non-responders/SRI(4) responders

BICLA non-response/SRI response, n (%)	SRI(4) responders/BICLA non-responders in TULIP-1
	Placebo (n=28)	Anifrolumab 300 mg (n=12)
BICLA non-response due to rash/ SRI response due to arthritis	20 (71.4)	5 (41.7)
BICLA non-response due to rash/ SRI response not due to arthritis	4 (14.3)	3 (25.0)
BICLA non-response on arthritis/ SRI response due to any reason	2 (7.1)	2 (16.7)
Other* BICLA non-response/ SRI response due to any reason	2 (7.1)	2 (16.7)

*Non-response due to a clinical manifestation other than rash or arthritis.

BICLA, British Isles Lupus Assessment Group-based Composite Lupus Assessment; SRI(4), Systemic Lupus Erythematosus Responder Index of ≥4.